How long do peptides stay in your system?

Because that is where the remainder stops mattering. After one half-life 50% is left, after two 25%, after three 12.5%, after four about 6%, and after five roughly 3%. The curve never technically reaches zero, so a convention is needed, and 97% eliminated is the one in general use.

It is a convention rather than a physical boundary. If you need a stricter threshold, seven half-lives puts you under 1%.

Not the number of half-lives, which is the counterintuitive part. Because elimination removes a fixed fraction rather than a fixed amount, a large dose and a small one both halve in the same interval.

What a larger dose changes is the absolute amount remaining at each step, not the timeline. Ten times the dose still takes five half-lives to fall to 3% — it just falls to 3% of a bigger number.

Then clearance starts from the accumulated plateau rather than from a single dose, so there is more to eliminate — but the five-half-lives span is unchanged, for the same proportional-elimination reason.

The practical implication is about where you start counting. The clock runs from the last dose, not the first, and levels at that moment are the steady-state level rather than a single-dose peak.

The small, unmodified ones — the growth hormone releasing factors and secretagogues, the short repair-model fragments, the neuropeptides. Several have half-lives measured in minutes, which puts total clearance inside a few hours.

There is nothing defective about that. Short duration is the natural state of a peptide, and in some cases it is the point: a compound meant to produce a pulse rather than a sustained level works better when it clears quickly.

The engineered metabolic compounds. Half-lives approaching or exceeding a week put total clearance past a month, which is why stopping a weekly GLP-1 is not a clean break — a meaningful fraction is still present weeks later.

Every one of those long half-lives is deliberate. The molecules carry structural features specifically added to resist enzymatic cleavage and renal filtration, because weekly dosing was a design target rather than a happy accident.

Most commonly, binding to albumin. A fatty-acid chain attached to the peptide binds reversibly to albumin in the blood, and the resulting complex is far too large for the kidney to filter. The peptide is released gradually from that reservoir, which stretches its effective lifetime enormously.

The alternative approach is fusion to a large carrier such as an antibody fragment, which achieves the same size-based protection by different means and tends to produce slower absorption and a flatter peak.

Time-to-peak ranges from minutes for small, rapidly absorbed peptides to a day or more for compounds formulated to release slowly from the injection site.

For long-acting compounds this matters less than it sounds, because absorption finishes well before elimination does. For short-acting ones the two overlap heavily, and the entire rise-and-fall can be over before anything resembling a plateau appears.

It changes how fast levels rise more than how long they persist. Sites differ in blood supply — the abdomen is typically best perfused, the thigh and buttock slower — so the front edge of the curve shifts.

Total elimination time is governed by the molecule's half-life, which the site does not alter. Heat, exercise and massage all accelerate uptake for the same perfusion reason, and all affect timing rather than duration.

Not necessarily. Tightly bound receptors release slowly, so occupancy can outlast measurable concentration. Signalling cascades continue after the signal that triggered them is gone. Changes to gene expression or to tissue structure persist on their own timeline entirely.

The reverse also happens: tolerance can blunt an effect while levels remain high. Half-life describes the molecule's exit, not the biology it set in motion, and reasoning from one to the other is where most confident-sounding wrong conclusions come from.

Clearance is the floor, not the answer. Five half-lives tells you when the compound has gone; it tells you nothing about when a receptor has resensitised or a suppressed axis has recovered, and those are usually the actual objectives of a break.

Those timelines are not derivable from pharmacokinetics and are genuinely a clinical question. What the calculation does give you is a lower bound — a break shorter than clearance is not a break in any meaningful sense.

Standard workplace and clinical panels screen for a defined list of substances — typically drugs of abuse — and peptides are not on it. A routine panel is not looking for them and will not find them incidentally.

That is a statement about what the test screens for, not about the compound being undetectable. A test designed to find something finds it.

Considerably longer than clearance from blood, in many cases. Anti-doping laboratories run dedicated assays for peptide hormones and their metabolites, and detection can rest on markers that persist after the parent compound has gone.

For any athlete subject to testing, reasoning about detection from a half-life figure is unsound. The five-half-lives rule describes elimination of the compound, not the lifetime of every trace it leaves.